secwatch.observer — SEC 8-K summary
======================================

Issuer:     MESA LABORATORIES INC /CO/ (MLAB)
CIK:        0000724004
Form:       8-K
Filed at:   2025-08-05T23:59:59+00:00
Accession:  0001437749-25-024714
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud

Mesa Laboratories Reports First Quarter Fiscal 2026 Results
-----------------------------------------------------------

- Total revenues increased 2.4% to $59,543,000 for the quarter ended June 30, 2025.
- Operating income decreased 45.1% to $3,064,000, impacted by FX and stock-based compensation.
- Clinical Genomics division revenue fell 10.7% core organic as China revenues contracted 69%.
- About $1.5M of expected Biopharmaceutical Development revenues shifted from Q1 to Q2 due to tariff surcharges.
- Non-GAAP adjusted operating income (excluding unusual items) was $12,902, down 15.9% year-over-year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/724004/000143774925024714/0001437749-25-024714-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/724004/000143774925024714/mlab20250804_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-024714

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer